Literature DB >> 33392640

FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.

Ya-Kun Liu1, Ya-Jing Jia2, Shi-Hao Liu2, Jing Ma2.   

Abstract

OBJECTIVE: To investigate the effects of FSTL1-mediated NF-κB signaling pathway on cisplatin (DDP) sensitivity of EOC cells.
METHODS: FSTL1 expression was determined in epithelial ovarian cancer (EOC) tissues and corresponding adjacent tissues using immunohistochemistry. SKOV3 and SKOV3/DDP cells were transfected and grouped into Blank, Vector, and FSTL1 groups. The sensitivity and 50% inhibitory concentration (IC50) of cells treated with different concentrations of DDP were detected by MTT assay. SKOV3/DDP cells were treated with 20 μM DDP, followed by evaluation of cell proliferation, cell apoptosis and determination of NF-κB pathway-related proteins while SKOV3 cells without.
RESULTS: FSTL1 expression in EOC tissues and cells was significantly down-regulated, especially decreased in DDP-resistant EOC cells SKOV3/DDP. In SKOV3 cells and SKOV3/DDP cells, the cell viability was reduced and the DDP sensitivity was improved with the decreased IC50 after over-expressing FSTL1. Compared with Blank group, FSTL1 group had declined number of SKOV3 cell colonies and increased cell apoptosis, with obvious up-regulations of FSTL1, Bax/Bcl-2 and cleaved caspase-3 expression and the down-regulations of p-IκBα, p-p65 and survivin expression. Combination of up-regulation of FSTL1 and DDP treatment can also effectively reduce cell colony forming, increase cell apoptosis, and inhibit NF-κB pathway activity of SKOV3/DDP cells. Moreover, this combination can also significantly suppress the growth of subcutaneous xenograft tumors in nude mice.
CONCLUSION: FSTL1 may inhibit NF-κB signaling pathway to suppress the growth and promote the apoptosis of epithelial ovarian cancer cells, and thereby enhancing its DDP sensitivity.

Entities:  

Keywords:  Cisplatin; Epithelial ovarian cancer; FSTL1; NF-κb; Sensitivity

Year:  2021        PMID: 33392640     DOI: 10.1007/s00280-020-04215-9

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  37 in total

1.  Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.

Authors:  Chen Hui; Zhang Lan; Lin Yue-li; Hong Li-lin; Huang Li-lin
Journal:  Reprod Sci       Date:  2015-06-15       Impact factor: 3.060

2.  Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1.

Authors:  Jing Zou; Ling Liu; Qi Wang; Fuqiang Yin; Zhijun Yang; Wei Zhang; Li Li
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

Review 3.  Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: a review.

Authors:  Hongye Ye; Anis Abdul Karim; Xian Jun Loh
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2014-06-20       Impact factor: 7.328

4.  Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis.

Authors:  Sreekanth P Reddy; Ramona Britto; Katyayni Vinnakota; Hebbar Aparna; Hari Kishore Sreepathi; Balaram Thota; Arpana Kumari; B M Shilpa; M Vrinda; Srikantha Umesh; Cini Samuel; Mitesh Shetty; Ashwani Tandon; Paritosh Pandey; Sridevi Hegde; A S Hegde; Anandh Balasubramaniam; B A Chandramouli; Vani Santosh; Paturu Kondaiah; Kumaravel Somasundaram; M R Satyanarayana Rao
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

5.  Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.

Authors:  Zhiqiang Han; Jing Feng; Zhenya Hong; Lijuan Chen; Wei Li; Shujie Liao; Xiaoli Wang; Teng Ji; Shixuan Wang; Ding Ma; Gang Chen; Qinglei Gao
Journal:  Biochem Biophys Res Commun       Date:  2013-05-07       Impact factor: 3.575

Review 6.  Resistance to chemotherapy in ovarian carcinoma.

Authors:  Hermann Lage; Carsten Denkert
Journal:  Recent Results Cancer Res       Date:  2007

Review 7.  Follistatin-like protein 1 and its role in inflammation and inflammatory diseases.

Authors:  Yury Chaly; Bruce Hostager; Sonja Smith; Raphael Hirsch
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

8.  Effects of FSTL1 on cell proliferation in breast cancer cell line MDA‑MB‑231 and its brain metastatic variant MDA‑MB‑231‑BR.

Authors:  Jiaqiang An; Lulu Wang; Yuanli Zhao; Qiang Hao; Ying Zhang; Jingyi Zhang; Chun Yang; Li Liu; Wenjuan Wang; Dongliang Fang; Tao Lu; Yan Gao
Journal:  Oncol Rep       Date:  2017-09-26       Impact factor: 3.906

9.  miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1.

Authors:  Yanan Wang; Wei Bao; Yuan Liu; Shiyu Wang; Shengjie Xu; Xi Li; Yanli Li; Sufang Wu
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

10.  Targeted therapies in epithelial ovarian cancer.

Authors:  Emma Dean; Loaie El-Helw; Jurjees Hasan
Journal:  Cancers (Basel)       Date:  2010-02-23       Impact factor: 6.639

View more
  6 in total

1.  Odd-skipped related 1 plays a tumor suppressor role in ovarian cancer via promoting follistatin-like protein 1 transcription.

Authors:  Zhong Yu; Ling Ouyang
Journal:  Hum Cell       Date:  2022-08-14       Impact factor: 4.374

2.  Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells.

Authors:  Alejandro Español; Yamila Sanchez; Agustina Salem; Jaqueline Obregon; Maria Elena Sales
Journal:  World J Clin Oncol       Date:  2022-06-24

Review 3.  The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer.

Authors:  Getinet M Adinew; Equar Taka; Patricia Mendonca; Samia S Messeha; Karam F A Soliman
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

4.  Hsa_circ_0058129 regulates papillary thyroid cancer development via miR-873-5p/follistatin-like 1 axis.

Authors:  Xiangrong Tan; Jiazheng Zhao; Jianlin Lou; Wen Zheng; Peng Wang
Journal:  J Clin Lab Anal       Date:  2022-04-04       Impact factor: 3.124

Review 5.  Cisplatin for cancer therapy and overcoming chemoresistance.

Authors:  Ranmali Ranasinghe; Michael L Mathai; Anthony Zulli
Journal:  Heliyon       Date:  2022-09-14

6.  CIRCNV: Detection of CNVs Based on a Circular Profile of Read Depth from Sequencing Data.

Authors:  Hai-Yong Zhao; Qi Li; Ye Tian; Yue-Hui Chen; Haque A K Alvi; Xi-Guo Yuan
Journal:  Biology (Basel)       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.